Clinical Trial Update: Study to Evaluate the Efficacy, Safety and Immunogenicity of Subcutaneous HX575 in the Treatment of Anemia Associated With Chronic Kidney Disease (SWEEP) [Phase 3]

View source ↗

Summary

The SWEEP Phase 3 trial evaluating HX575 for anemia associated with chronic kidney disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Chronic Kidney Disease

Drugs mentioned

• HX575 (epoetin alfa)

Snippet

Sponsor: Sandoz | Conditions: Anemia, Chronic Renal Insufficiency | Phase 3 | Status: WITHDRAWN